Evidence map›Paper›PMID 27500269›Full record

ArticleTransplantation direct2016

Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation.

Allison Tong, Klemens Budde, John Gill, Michelle A Josephson, Lorna Marson, Timothy L Pruett, Peter P Reese, David Rosenbloom, Lionel Rostaing, Anthony N Warrens and 14 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Transplantation direct, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06474273 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter Randomized Controlled Trial to Treat Acute t Cell Mediated Rejection in Kidney and Kidney-pancreas Transplant Recipients

TypeinterventionalSponsorUniversity of SydneyRan2026 to 2030Enrolled540ConditionsRejection, Transplant, Kidney, Rejection, Transplant, PancreasArmsMethylprednisolone, Prednisone
NCT07415421 narecruitingnot on this mapstarted 2026, after this paper: background citation

Subtotal Parathyroidectomy for the Treatment of Persistent Hyperparathyroidism After Kidney Transplantation

TypeinterventionalSponsorAarhus University HospitalRan2026 to 2030Enrolled85ConditionsHyperparathyroidism, Kidney Transplantation RecipientsArmsSubtotal Parathyroidectomy, Conservative Management
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Circulating serum microRNAs in kidney transplant recipients with post-transplant malignancies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Age and gender differences in symptom experience and health-related quality of life in kidney transplant recipients: a cross-sectional study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  13. Clinical journal of the American Society of Nephrology : CJASN · 2022
    Review
  14. Review
  15. Urinary Excretion ofNutrients · 2020
    Article
  16. Urinary Excretion ofJournal of clinical medicine · 2019
    Article
  17. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Article
  18. PPI in research: a reflection from early stage researchers.Research involvement and engagement · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 6 countries.

Allison TongSydney School of Public Health, The University of Sydney, Sydney, Australia.; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.
Klemens BuddeDepartment of Nephrology, Charité-Universitätsmedizin, Berlin, Germany.
John GillDivision of Nephrology, University of British Columbia, Vancouver, Canada.
Michelle A JosephsonDepartment of Medicine, The University of Chicago, Chicago, IL.
Lorna MarsonTransplant Unit, University of Edinburgh, Edinburgh, United Kingdom.
Timothy L PruettDepartment of Surgery, University of Minnesota, Minneapolis, MN.
Peter P ReeseRenal Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
David RosenbloomESRD Network 18, Los Angeles, CA.
Lionel RostaingDepartment of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire Rangueil, Toulouse, France.
Anthony N WarrensSchool of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Germaine WongSydney School of Public Health, The University of Sydney, Sydney, Australia.; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.; Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia.
Jonathan C CraigSydney School of Public Health, The University of Sydney, Sydney, Australia.; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.
Sally CroweCrowe Associates Ltd, Oxford, United Kingdom.
Tess HarrisPKD International, London, United Kingdom.
Brenda HemmelgarnDepartments of Medicine and Community Health Sciences, Libin Cardiovascular Institute and O'Brien Institute of Public Health, University of Calgary, Calgary, Canada.
Braden MannsDepartments of Medicine and Community Health Sciences, Libin Cardiovascular Institute and O'Brien Institute of Public Health, University of Calgary, Calgary, Canada.
Peter TugwellDepartment of Medicine, University of Ottawa, Ottawa, Canada.
Wim Van BiesenRenal Division, Ghent University Hospital, Ghent, Belgium.
David C WheelerCentre for Nephrology, University College London, London, United Kingdom.
Wolfgang C WinkelmayerSelzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, TX.
Nicole EvangelidisSydney School of Public Health, The University of Sydney, Sydney, Australia.; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.
Benedicte SautenetSydney School of Public Health, The University of Sydney, Sydney, Australia.; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.; Department of Nephrology and Clinical Immunology, University Francois Rabelais, Tours, France.
Martin HowellSydney School of Public Health, The University of Sydney, Sydney, Australia.; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.
Jeremy R ChapmanCentre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia.
The University of Sydney · AUChildren's Hospital at Westmead · AUUniversity of Minnesota · USBaylor College of Medicine · USCharité - Universitätsmedizin Berlin · DELibin Cardiovascular Institute of Alberta · CAO'Brien Institute · AUQueen Mary University of London · GBUniversity College London · GBUniversity of British Columbia · CAUniversity of Chicago · USUniversity of Edinburgh · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough advances in treatment have dramatically improved short-term graft survival and acute rejection in kidney transplant recipients, long-term graft outcomes have not substantially improved. Transplant recipients also have a considerably increased risk of cancer, cardiovascular disease, diabetes, and infection, which all contribute to appreciable morbidity and premature mortality. Many trials in kidney transplantation are short-term, frequently use unvalidated surrogate endpoints, outcomes of uncertain relevance to patients and clinicians, and do not consistently measure and report key outcomes like death, graft loss, graft function, and adverse effects of therapy. This diminishes the value of trials in supporting treatment decisions that require individual-level multiple tradeoffs between graft survival and the risk of side effects, adverse events, and mortality. The Standardized Outcomes in Nephrology-Transplantation initiative aims to develop a core outcome set for trials in kidney transplantation that is based on the shared priorities of all stakeholders.

methodsThis will include a systematic review to identify outcomes reported in randomized trials, a Delphi survey with an international multistakeholder panel (patients, caregivers, clinicians, researchers, policy makers, members from industry) to develop a consensus-based prioritized list of outcome domains and a consensus workshop to review and finalize the core outcome set for trials in kidney transplantation.

conclusionsDeveloping and implementing a core outcome set to be reported, at a minimum, in all kidney transplantation trials will improve the transparency, quality, and relevance of research; to enable kidney transplant recipients and their clinicians to make better-informed treatment decisions for improved patient outcomes.

Identifiers

PMID27500269
PMCPMC4946524
OpenAlexW2404807949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.